deucravacitinib
bms
['lupus', 'deucra']
congress #acr22 | marilyn pike discussed 48 week results from a phase ii trial of deucravacitinib in pts with active #sle. adverse event rates were similar between deu and placebo treated pts, with the primary endpoint being met at week 32. #lupus 
An online resource, dedicated to providing information and up-to-date medical education within the lupus space.